The influence factors of clinical efficacy and prognosis of breast cancer patients treated with neoadjuvant chemotherapy

Abstract

Objective To investigate predictive indicators of clinical efficacy and prognosis of breast cancer patients treated with neoadjuvant chemotherapy. Methods 290 female patients with breast cancer who treated with neoadjuvant chemotherapy were enrolled in this study. The collected data including tumor position, tumor size, cTNM staging, LNR, pathological molecular types(including ER, PR, Her-2, Ki-67 and so on), neoadjuvant chemotherapy regimens, pathological complete response rate, postoperative treatment and survival time. Results Neoadjuvant chemotherapy curative effect was related to pausimenia, T staging, N staging, ER/PR and Ki-67(P < 0.05), N staging (OR = 0.041, 95% CI = 0.012 ~ 0.134) and Ki-67 (OR = 9.340, 95% CI = 1.770 ~ 49.286) were independent risk factors of pCR. Recurrence of metastases was related to T staging, LNR, Ki-67, ET regimen, postoperative chemotherapy and postoperation radiotherapy(P < 0.05), T staging (OR = 1.731, 95%CI = 1.244 ~ 2.408), LNR (OR = 2.726, 95%CI = 1.430 ~ 5.197) and Ki-67 (OR = 3.107, 95%CI = 1.395 ~ 6.920) were independent risk factors of recurrence of metastases. Patients with low Ki-67 expression, low LNR, T1 staging and T2 staging and N0/N1/N2 staging had a better prognosis. Conclusion Clinical efficacy and prognosis of breast cancer patients treated with neoadjuvant chemotherapy were related to cTNM staging, LNR, ER/PR and Ki-67.